Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $3.1 million.

  • Foghorn Therapeutics' Depreciation & Amortization (CF) rose 28.57% to $900,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 3.46%. This contributed to the annual value of $3.1 million for FY2024, which is 10.86% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Depreciation & Amortization (CF) of $3.1 million as of FY2024, which was down 10.86% from $3.5 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Depreciation & Amortization (CF) peaked at $3.5 million during FY2023, and registered a low of $1.3 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $3.3 million (2022), whereas its average is $3.3 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Depreciation & Amortization (CF) spiked by 143.18% in 2021, and later declined by 10.86% in 2024.
  • Foghorn Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $1.3 million in 2020, then soared by 143.18% to $3.2 million in 2021, then increased by 2.91% to $3.3 million in 2022, then rose by 5.39% to $3.5 million in 2023, then fell by 10.86% to $3.1 million in 2024.